Favipiravir is used to treat new or re-epidemic influenza in adults (only used when other anti-influenza virus drugs are ineffective or ineffective.
Favipiravir (also known as "Favipiravir")[1]_, is a new type of RNA-dependent RNA polymerase (RdRp) inhibitor, a broad-spectrum anti-influenza virus drug, used to treat new and recurrent influenza.
Favipiravir is a new broad-spectrum anti-RNA virus drug, and the new coronavirus is an RNA single-stranded virus. Research shows that in addition to influenza viruses, the drug also shows good resistance to a variety of RNA viruses. Virus effects, such as Ebola virus, arenavirus, bunya virus, rabies virus, etc.
Favipiravir’s original drug AVIGAN_ was developed by Fujifilm Group Toyama Chemical Industry Co., Ltd. in 2014. In March 2016, Favipiravir was approved for marketing in Japan and became Japan’s national strategic reserve drug. In June 2016, Hisun Pharmaceutical signed an exclusive licensing agreement for compound patents with Japan’s Toyama Chemical Industry Co., Ltd. China develops, manufactures and sells anti-influenza virus drugs containing favipiravir.